Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05392946 · ClinicalTrials.gov registry record · Phase 1

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

A Phase 1 study of Plasma Cell Myeloma, sponsored by Mayo Clinic.

Active
Registry status
Phase 1
Development phase
49
Enrollment target
1
Study location

NCT05392946 is a Phase 1 study of Plasma Cell Myeloma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 49 participants, below the 207-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05392946, a Phase 1 study of Plasma Cell Myeloma, is active but no longer recruiting, sponsored by Mayo Clinic.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
49 participants
Enrollment target
1
Study location

Study Summary

This phase I/II trial studies the side effects and best dose of iberdomide and how well it works in combination with daratumumab, bortezomib, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving iberdomide in combination with daratumumab, bortezomib, and dexamethasone may kill more cancer cells in patients with newly diagnosed multiple myeloma.

Conditions Studied

Plasma Cell Myeloma

Interventions

  • DRUG Dexamethasone
  • BIOLOGICAL Daratumumab
  • DRUG Iberdomide
  • DRUG Bortezomib

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2022-08-11
Est. Completion 2028-05-31
Phase Phase 1

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05392946

The ClinicalTrials.gov registry entry for NCT05392946 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 207-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (76% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Plasma Cell Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.

NCT05392946 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT05392946 about?

NCT05392946 is a clinical study titled "Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study". This phase I/II trial studies the side effects and best dose of iberdomide and how well it works in combination with daratumumab, bortezomib, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Immunotherapy with iberdomide, may induce changes in body's immune system and ma...

What is the current status of trial NCT05392946?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2022-08-11. Estimated completion is 2028-05-31.

What conditions does trial NCT05392946 study?

This clinical trial studies the following conditions: Plasma Cell Myeloma.

What interventions are being tested in trial NCT05392946?

The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (BIOLOGICAL), Iberdomide (DRUG), Bortezomib (DRUG).

Who is sponsoring clinical trial NCT05392946?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05392946 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Plasma Cell Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Plasma Cell Myeloma

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.